Rates of administration of adjuvant neratinib increased steadily following the publication of the ExteNET trial results in November 2017, reaching a peak in May 2018 when approximately 30% of patients with high-risk, early-stage HER2-positive breast cancer were treated with adjuvant neratinib (Fig. 2). Here, ERBB2 is linked to breast carcinoma.